key: cord-1011386-mbasdyhf
authors: Tahvildari, Azin; Arbabi, Mahta; Farsi, Yeganeh; Jamshidi, Parnian; Hasanzadeh, Saba; Calcagno, Tess Moore; Nasiri, Mohammad Javad; Mirsaeidi, Mehdi
title: Clinical Features, Diagnosis, and Treatment of COVID-19 in Hospitalized Patients: A Systematic Review of Case Reports and Case Series
date: 2020-05-15
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2020.00231
sha: d02380684904ca264f7f22e63d1a45949b596c9f
doc_id: 1011386
cord_uid: mbasdyhf

Introduction: The 2019 novel coronavirus (COVID-19) has been declared a public health emergency worldwide. The objective of this systematic review was to characterize the clinical, diagnostic, and treatment characteristics of hospitalized patients presenting with COVID-19. Methods: We conducted a structured search using PubMed/Medline, Embase, and Web of Science to collect both case reports and case series on COVID-19 published up to April 24, 2020. There were no restrictions regarding publication language. Results: Eighty articles were included analyzing a total of 417 patients with a mean age of 48 years. The most common presenting symptom in patients who tested positive for COVID-19 was fever, reported in up to 62% of patients from 82% of the analyzed studies. Other symptoms including rhinorrhea, dizziness, and chills were less frequently reported. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19 (21%). CT images displayed ground-glass opacification (GGO) patterns (80%) as well as bilateral lung involvement (69%). The most commonly used antiviral treatment modalities included, lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). Conclusions: Development of ARDS may play a role in estimating disease progression and mortality risk. Early detection of elevations in serum CRP, combined with a clinical COVID-19 symptom presentation may be used as a surrogate marker for the presence and severity of the disease. There is a paucity of data surrounding the efficacy of treatments. There is currently not a well-established gold standard therapy for the treatment of diagnosed COVID-19. Further prospective investigations are necessary.

Late in December 2019 and early in January 2020, reports of a very progressive pneumonia-like respiratory syndrome, starting in Wuhan, China, induced global health concerns (1) . Soon after the onset of disease, it was found that the pathogen was a new member of the coronaviridae family, named SARS-COV-2 which is now called 2019-n-CoV (2) . The respiratory syndrome caused by 2019-n-CoV is called COVID-19. COVID-19 is characterized by low-grade fever, cough, dyspnea, lymphopenia, and groundglass opacities on chest CT scan (3, 4) . COVID-19 is a highly contagious disease, probably an aerosol born one, with human to human transmission capacity which has implicated many countries all around the world (5) . In this review article, we systematically surveyed case reports and case series from many countries in the world to give a picture of the epidemiology, clinical presentations, laboratory changes, imaging findings, diagnostic criteria, treatments, outcomes, prognostic factors, and risk factors of COVID-19 in hospitalized patients.

This review conforms to the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) statement (6) .

We carried out systematic searches of the literature in the following bibliographical databases: PubMed/Medline, Embase, and Web of Science. Search criteria included case reports and case series articles published up to April 24, 2020 , and there were no restrictions regarding publication language. We used Google Translate for eligible articles published in languages other than English. The search terms for our review were: COVID-19, severe acute respiratory syndrome coronavirus 2, novel coronavirus, SARS-CoV-2, nCoV disease, SARS2, COVID-19, 2019-nCoV, coronavirus disease-19, coronavirus disease 2019, and 2019 novel coronavirus.

Studies included in the review met the following criteria: prospective or retrospective descriptive case reports and case series of COVID-19 in the hospital setting which included diagnostic methods, clinical manifestations, laboratory features, treatment, and outcomes. Articles describing experimental approaches as well as reviews and publications without peerreview processes were excluded.

All potentially relevant articles were screened in two stages for eligibility. In the first stage, the titles and abstracts of potentially relevant articles were screened independently by two reviewers (YF, PJ). In the second stage of assessment, the full text of those abstracts which met the inclusion criteria was retrieved and independently reviewed by the same authors. Disagreements and technical uncertainties were discussed and resolved between review authors (AT, SH, MA, MJN).

The extracted data included bibliographic data, patient demographics (e.g., age and gender), radiological and laboratory findings, treatment protocols, and medical consequences. Two authors (AT, SH) independently extracted the data from the selected studies. The data was jointly reconciled, and disagreements were discussed and resolved between review authors (YF, PJ, MA, MJN).

The critical appraisal checklist for case reports provided by the Joanna Briggs Institute (JBI) was used to perform a quality assessment of the studies (7). Figure 1 , our systematic search resulted in an initial number of 6,004 of potentially relevant articles, of which 1,033 were excluded by title and abstract evaluation. Applying the inclusion/exclusion criteria to the full-text documents, 80 articles were eligible for inclusion in the systematic review. 42 case reports and 38 case series from 19 countries were identified with a total of 417 unique cases of COVID-19 with a mean age of 48 years ( Table 1) . The included case reports were published because of the following reasons: they reported (1) new CT findings; (2) new clinical manifestations; (3) new laboratory findings, (4) new treatment outcomes; (5) atypical manifestations and some were the first one in a specific country. Based on the JBI tool, the included studies had a low risk of bias. RT-PCR COVID-19 was present in 79 (95%) articles as inclusion criteria. In addition to RT-PCR, a CT scan served as a diagnostic tool in 16 (19%) of papers. Reported comorbidities included hypertension, diabetes, cardiovascular disease, and pulmonary disease. Hypertension was investigated the most, studied in 22/83 (26.5%) of papers. Of the 16 COVID-19 positive patients found in the studies investigating hypertension, 44 patients were hypertensive (19%) ( Table 2) . Lymphopenia was reported in 24 studies which identified 83/185 (45%) of COVID-19 positive patients. Additionally, in studies that reported C-reactive protein (CRP) measurements, a large majority of patients displayed an elevated CRP (60%). CT images commonly displayed groundglass opacification (GGO) patterns (82%) as well as bilateral lung involvement (66%). Progression to acute respiratory distress syndrome (ARDS) was the most common complication of patients testing positive for COVID-19. We found 11/83 (13.2%) reports on Acute Respiratory Distress Syndrome (ARDS), 18 of 86 (21%) investigated cases had ARDS. Mortality outcomes were difficult to assess; only 10 studies showed mortality data in which 17/108 (16%) COVID-19 patients died. A wide range of therapeutic modalities was tried across studies, with antiviral treatments being the most used.

Common antiviral treatment modalities included lopinavir (HIV protease inhibitor), arbidiol hydrochloride (influenza fusion inhibitor), and oseltamivir (neuraminidase inhibitor). In Table 3 we summarize all of the drugs used. 

The 2019 novel coronavirus has been declared a public health emergency worldwide. The World Health Organization (WHO) declared COVID-19 a pandemic affecting 110 countries around the world with a continued global spread. The 2019-nCoV is likely to be transmitted by asymptomatic individuals (86) . Asymptomatic transfer leads to lower prevalence estimates and higher transmission rates in the community. Until universal screening and vaccination become available, it is necessary to trace close contacts of those testing positive for COVID-19 and quarantining contacts to prevent asymptomatic transmission.

According to the articles we included, 2019-nCoV can only be transferred from person to person (87) . Chen et al. suggested that they had no evidence of vertical transmission from mother to child (36) . Any person infected with 2019-nCoV can develop a clinical course of Covid-19. However, it is reported to cause the most severe symptoms such as respiratory failure in older men with comorbidities (88) . Children, teenagers, and younger people mostly showed a mild presentation of the disease (89) .

Based on our reviewed articles, hypertension, diabetes, cardiovascular disease, and pulmonary disease were the most common morbidities among COVID-19 patients. This point was also mentioned in Alraddadi et al. study about MERS-CoV patients (90) . They showed that individuals with comorbidities like diabetes, smoking, and cardiovascular disease were associated with a more severe clinical course (90) . According to Yang et al., chronic diseases can debilitate the immune system and make pro-inflammatory conditions, leading to more severe infection and subsequently higher mortality rates (91) .

According to the included studies, the most common clinical manifestations were fever, cough, dyspnea, and myalgia or fatigue. Less common clinical manifestations included nausea or vomiting, dizziness, rhinorrhea, and chills. Liu et al. reported that infants had mild clinical manifestations and a better prognosis. Furthermore, some asymptomatic cases were seen among children. The most common abnormal laboratory changes were lymphopenia, high concentrations of C-reactive protein, and elevated levels of aspartate aminotransferase; however, we do not know the exact pathogenesis and the reason for these alterations. Laboratory abnormalities may indicate the severity of disease and developing complications. According to Huang et al., most patients with secondary infection had a procalcitonin level >0.5 ng/Ml and ICU patients had higher levels of prothrombin time and D-dimer (92) . Also, Liu et al. mentioned using hypoalbuminemia, lymphopenia, high concentrations of CRP, and elevated LDH to predict the severity of acute lung injury (3) . Higher levels of angiotensin II are also proposed to be related to acute lung injury (3) . Meanwhile, nonsurvivors are suggested to have higher D-dimer and FDP levels, longer PT and aPTT, and lower fibrinogen and antithrombin levels (93) .

CT scan as a diagnostic tool can be used to evaluate the severity of pulmonary involvement and monitor clinical progression. CT scan has good sensitivity and can be used to establish COVID-19 diagnosis in patients who are highly suspicious based on epidemiologic history and clinical manifestations but have negative PCR-based test results (12, 94) . It is important to highlight that the CT scan can be normal during initial days, and a normal CT scan in a suspected case would never definitely rule out the diagnosis of COVID-19 (95) . Moreover, the CT scan is dynamic in patients with COVID-19 and changes rapidly (13, 17, 19) . The earliest abnormal finding in the CT scan is the appearance of ground-glass opacities in peripheral and sub-pleural areas (96) . As the disease progresses, the GGO's will expand and distribute more, most commonly to the right lower lung lobes. Later findings include consolidations, paving patterns, thickening of lobar fissures, and adjacent pleura. Pleural effusion, hilar lymphadenopathies, and mediastinal lymphadenopathies are not common findings and have only been reported scarcely (40) . Lung pathology can progress to a "white lung" with low functional capacity or heal with some fibrotic remnants (40) . Dynamic changes in the lungs seen on CT imaging will continue even after the patient's discharge (96) . CT scan findings have prognostic value in some patients, as Shi et al. have reported, deterioration on follow-up CT scan, old age, male sex, and underlying comorbidities are associated with poor prognosis. ARDS was the most common complication among the confirmed COVID-19 patients; the development of ARDS increased the risk of patient mortality (97) . Huang et al. reported that the median time from onset of symptoms to the development of ARDS was 9 days (92). Other complications were acute cardiac injury, acute kidney injury, secondary infection, and shock that leads to multiple organ failure (98, 99) . ICU patients in comparison to non-ICU patients were also more likely to have complications (100) . The mortality rate was higher in critically ill patients as well as in older patients with comorbidities and ARDS. Yang et al. reported that the median duration from ICU admission to death was 7 days (97) . The window between the presentation to the time of ICU admission and/or development of ARDS is an optimal time for medical intervention.

Also, the results of the current study are in comparison with the recent large patient cohort studies in the aspect of comorbidities, clinical manifestations, laboratory, and radiological findings, however, there are some differences (101, 102) . In a study by Richardson et al., a more detailed analysis of the patient's vital signs, ICU interventions, outcome characteristics, and risk factors were reported (101) . According to their study, among the patients who were discharged or had died during hospitalization, 14.2% were treated in the ICU, 12.2% received invasive mechanical ventilation, 3.2% were treated with kidney replacement therapy, and 21% died. Moreover, Grasselli et al. indicated that Older patients (age ≥ 64 years) had higher mortality than younger patients (age ≤ 63 years) (36%vs 15%) (102) .

There are many challenges in COVID-19 therapeutic strategies. There is currently no cure for COVID-19. However, pharmacologic and non-pharmacologic symptom management and supportive care measures should be given to all patients with symptomatic COVID-19. Other various therapeutic strategies have been trialed in patients with COVID-19 to slow disease progression. There is a paucity of data surrounding the efficacy of treatments. Of the case controls and case series we included, antiviral agents including HIV protease inhibitors (lopinavir and ritonavir) as well as anti-influenza compounds (oseltamivir and arbidol) were used as treatment regimens. Unfortunately, we didn't have enough information about the efficacy of each regimen; however, according to some studies, anti-HIV based medications could have benefits in more rapid improvement of clinical manifestations and decrease in viral load (13, 16, 19) .

A limitation of this review relates to the potential risk of bias. Bias occurs in the case reports/series studies because their results are not representative and do not represent the truth. A further limitation is that the conclusions are limited due to the case reports and case series. We did not include observational studies and randomized controlled trial (RCT)/quasi-randomized studies, because another study being conducted by the authors. Furthermore, the focus of the reviewed case reports and case series was mainly on the clinical description of the patients with COVID-19, but detailed information on the treatment outcomes and medical consequences were rarely provided. Also, the case number included in this systematic review is low compared with the currently published patient cohort, and this may lead to the declining clinical significance of this manuscript. Finally, our results are limited to younger adults who had been hospitalized during the 4-5 first months of the COVID-19 pandemic.

In conclusion, we discussed the clinical symptoms, laboratory abnormalities, common comorbidities, imaging modalities, and potential therapeutic options in COVID-19. We indicated that the most common symptoms were fever, cough, and dyspnea, but some young infected cases had no signs or symptoms. ARDS was the most common reported complication and was associated with poor prognosis. In the wake of the COVID-19 pandemic, countries are scrambling to produce enough RT-PCR diagnostic tests. Diagnostic information from other surrogate markers would be valuable if markers proved to be sensitive and specific. Namely, we learned that laboratory data like CRP may not only be related to the severity of the disease, but it may be predictive of disease outcomes. Further studies are needed to relate quantified elevations in CRP to disease severity. Due to the high sensitivity of the CT scan, it is considered as a good diagnostic tool. However, it should be kept in mind that a normal CT scan will never rule out the diagnosis of COVID-19 in a highly suspicious case based on history and clinical findings. Lastly, there are different therapeutic strategies for COVID-19 patients, but we don't have enough data for their efficacy. Additional investigations including randomized controlled trials will be necessary to further our understanding of the treatment of COVID-19.

All datasets presented in this study are included in the article/ supplementary material.

MN and MM designed the study and revised the manuscript. MN, AT, MA, YF, PJ, SH, and TC performed the search, data extraction, statistical analysis, and wrote the first draft of the manuscript. 

A novel coronavirus from patients with pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection

Pathogenicity and transmissibility of 2019-nCoV-a quick overview and comparison with other emerging viruses

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Review: Checklists for Case Reports

Viral load kinetics of SARS-CoV-2 infection in first two patients in Korea

A familial cluster of infection associated with the 2019 novel coronavirus indicating potential personto-person transmission during the incubation period

The first 2019 novel coronavirus case in Nepal

Pre-and posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia

Changes of CT findings in a 2019 novel Coronavirus (2019-nCoV) pneumonia patient

The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019

The 2019 novel cornoavirus pneumonia with onset of oculomotor nerve palsy: a case study

First case of 2019 novel coronavirus in the United States

Case of the index patient who caused tertiary transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR

Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan

First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia

novel Coronavirus (COVID-19) pneumonia: serial computed tomography findings

A new coronavirus associated with human respiratory disease in China

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple cases

CT manifestations of two cases of 2019 novel coronavirus (2019-nCoV) pneumonia

Novel coronavirus pneumonia outbreak in 2019: computed tomographic findings in two cases

A Locally transmitted case of SARS-CoV-2 infection in Taiwan

Importation and human-to-human transmission of a novel coronavirus in Vietnam

Journey of a Thai Taxi driver and novel coronavirus

First Atypical case of 2019 novel coronavirus in Yan'an, China

Clinical features of atypical 2019 novel coronavirus pneumonia with an initially negative RT-PCR assay

2019-novel coronavirus infection in a three-month-old baby

Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province. Zhonghua Fang Xue Za Zhi

First case of 2019 novel coronavirus infection in children in Shanghai

First case of neonate infected with novel coronavirus pneumonia in China

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating personto-person transmission: a study of a family cluster

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records

Novel coronavirus infection in hospitalized infants under 1 year of age in China

18 F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases

Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment

Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing

Chest radiographic and CT findings of the 2019 Novel Coronavirus Disease (COVID-19): analysis of nine patients treated in Korea

First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Presumed asymptomatic carrier transmission of COVID-19

Potential Presymptomatic Transmission of SARS-CoV-2

Analysis of CT features of 15 children with 2019 novel coronavirus infection

Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing

Clinical characteristics of 30 medical workers infected with new coronavirus pneumonia

2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: an uncommon radiological presentation

Lung involvement found on chest ct scan in a pre-symptomatic person with SARS-CoV-2 infection: a case report

Chest imaging in patients hospitalized with COVID-19 infection-a case series

Dynamic chest ct evaluation in three cases of 2019 novel coronavirus pneumonia

Epidemiologic and Clinical characteristics of 26 cases of COVID-19 arising from patient-to-patient transmission in Liaocheng, China

Clinical features and multidisciplinary treatment outcome of COVID-19 pneumonia: a report of three cases

Alert for non-respiratory symptoms of Coronavirus Disease 2019 (COVID-19) patients in epidemic period: a case report of familial cluster with three asymptomatic COVID-19 patients

Asymptomatic novel coronavirus pneumonia patient outside Wuhan: the value of CT images in the course of the disease

The first COVID-19 case in Afghanistan acquired from Iran

CT morphology of COVID-19: Case report and review of literature

Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India

Chest radiography and computed tomography findings from a Brazilian patient with COVID-19 pneumonia

A family cluster of severe acute respiratory syndrome coronavirus 2 infections

Diagnosis and management of first case of COVID-19 in Canada: lessons applied from SARS

Coronavirus-19 Disease (COVID-19): a case series of early suspects reported and the implications towards the response to the pandemic in Zimbabwe

Radiographic and clinical features of children with 2019 novel coronavirus (COVID-19) pneumonia

Atypical presentation of SARS-CoV-2 infection: a case report

Clinical and transmission characteristics of Covid-19-a retrospective study of 25 cases from a single thoracic surgery department

First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan

First COVID-19 infections in the Philippines: a case report

A case report of COVID-19 with false negative RT-PCR test: necessity of chest CT

COVID-19: a case series to support radiographer preliminary clinical evaluation

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

CT image of novel coronavirus pneumonia: a case report

Case report on early diagnosis of COVID-19

Common CT findings of novel Coronavirus Disease 2019 (COVID-19): a case series

Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha

A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs

novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the korean cohort study on COVID-19

The first case of 2019 novel coronavirus pneumonia imported into Korea from Wuhan, China: implication for infection prevention and control measures

Early epidemiological and clinical characteristics of 28 cases of coronavirus disease in South Korea

A case of COVID-19 and pneumonia returning from Macau in Taiwan: clinical course and anti-SARS-CoV-2 IgG dynamic

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Fatal outcome of coronavirus disease 2019 in a previously healthy 50-year-old man

Clinical study and CT findings of a familial cluster of pneumonia with Coronavirus Disease 2019 (COVID-19)

SARS-CoV-2 viral load in upper respiratory specimens of infected patients

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2

Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia

Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases

Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection

CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Copyright © 2020 Tahvildari, Arbabi, Farsi, Jamshidi, Hasanzadeh, Calcagno, Nasiri and Mirsaeidi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.